Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

End-of-Life Outcomes in Patients with Acute Myeloid Leukemia Receiving Non-Curative Chemotherapy

Richa Thakur, Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Bradley Goldberg, Erin Jou, Jonathan E Kolitz, David W Chitty

Blood (2023) 142 (Supplement 1): 3807.

https://doi.org/10.1182/blood-2023-190266

Published: 2023

Journal Articles

Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax

Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Richa Thakur, Bradley Goldberg, Erin Jou, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 2904.

https://doi.org/10.1182/blood-2023-190272

Published: 2023

Journal Articles

Outcomes and Hospital Resource Utilization Associated with Decreased Ven Exposure in Acute Myeloid Leukemia Patients: A Real-World Retrospective Review

Stephanie Boisclair, Phyu Thin Naing, Edward Zhou, Richa Thakur, Erin Jou, Bradley Goldberg, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2023-185079

Published: 2023

Journal Articles

Differences in Molecular Alterations and Clinical Outcomes By Ethnicity for Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Edward Zhou, Stephanie Boisclair, Phyu Thin Naing, Richa Thakur, Bradley Goldberg, Erin Jou, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 7427.

https://doi.org/10.1182/blood-2023-185014

Published: 2023

Journal Articles

Association between Neutropenic Index for Venetoclax Exposure (NIVE) and Survival Outcomes Among AML Patients Highlighting Racial Disparities

Phyu Thin Thin Naing, Stephanie Boisclair, Edward Zhou, Richa Thakur, Erin Jou, Bradley Goldberg, David W Chitty, Jonathan E Kolitz

Blood (2023) 142 (Supplement 1): 4219.

https://doi.org/10.1182/blood-2023-190410

Published: 2023

Journal Articles

Diffuse Large B-Cell Lymphoma CNS Relapse Prophylaxis with Intrathecal or High-Dose Intravenous Methotrexate

Edward Zhou, Kelvin Zheng, Phyu Thin Naing, Stephanie Boisclair, Bradley Goldberg

Blood (2023) 142 (Supplement 1): 6252.

https://doi.org/10.1182/blood-2023-172831

Published: 2023

Journal Articles

Outcomes with Venetoclax Dose De-Escalation and Variable Cycle Intervals: A Real-World AML Survival Analysis

Stephanie Boisclair, Edward Zhou, Phyu Thin Naing, David Chitty, Jonathan E. Kolitz

Blood (2022) 140 (Supplement 1): 9023–9024.

https://doi.org/10.1182/blood-2022-169966

Published: 2022

Journal Articles

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Stephanie Boisclair, MD, Richie Uba, PharmD, Amanda Brahim, PharmD, Fernando Vargas Madueno, MD, Julio C. Chavez, MD, Jose Sandoval-Sus, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143226

Published: 2020

Journal Articles

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Jose Sandoval-Sus, MD, Franco Castillo Tokumori, MD, Ning Dong, MD, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Damaal Walker, PharmD, Sanjay Bridgelall, MD, Ling Zhang, MD, Hayder Saeed, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140070

Published: 2020

Journal Articles

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Yazan Numan, MD, Zaid Abdel Rahman, MD, Justin Grenet, MD, Stephanie Boisclair, MD, Jan Philipp Bewersdorf, MD, Dylan Barth, PharmD, BCPS, Amer M. Zeidan, MBBS, MHS, Musa Yilmaz, MD, Shira Dinner, MD, Yehuda E. Deutsch, MD, Olga Frankfurt, MD, Mark Litzow, MD, Aref Al-Kali, MD, James M. Foran, MD, Lisa Z. Sproat, MD, Borko Jovanovic, PhD, Naval Daver, MD, Alexander E. Perl, MD, Jessica K. Altman, MD

Blood (2020) 136 (Supplement 1): 5–7.

https://doi.org/10.1182/blood-2020-137251

Published: 2020

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

NARROW

End-of-Life Outcomes in Patients with Acute Myeloid Leukemia Receiving Non-Curative Chemotherapy

Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax

Outcomes and Hospital Resource Utilization Associated with Decreased Ven Exposure in Acute Myeloid Leukemia Patients: A Real-World Retrospective Review

Differences in Molecular Alterations and Clinical Outcomes By Ethnicity for Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Association between Neutropenic Index for Venetoclax Exposure (NIVE) and Survival Outcomes Among AML Patients Highlighting Racial Disparities

Diffuse Large B-Cell Lymphoma CNS Relapse Prophylaxis with Intrathecal or High-Dose Intravenous Methotrexate

Outcomes with Venetoclax Dose De-Escalation and Variable Cycle Intervals: A Real-World AML Survival Analysis

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only